These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 6542016)
1. Influence of concomitant infusion of thymidine and inosine on methotrexate activity in normal and P388-bearing mice. Uitendaal MP; Schornagel JH; Leyva A; Pinedo HM Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1527-32. PubMed ID: 6542016 [TBL] [Abstract][Full Text] [Related]
2. Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine. Semon JH; Grindey GB Cancer Res; 1978 Sep; 38(9):2905-11. PubMed ID: 679199 [No Abstract] [Full Text] [Related]
3. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy. Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122 [TBL] [Abstract][Full Text] [Related]
4. Modulation versus rescue of antimetabolite toxicity by salvage metabolites administered by continuous infusion. Grindey GB; Semon JH; Pavelic ZP Antibiot Chemother (1971); 1978; 23():295-304. PubMed ID: 306219 [TBL] [Abstract][Full Text] [Related]
5. Synergism between purines and thymidine (TDR) in reversal of methotrexate (MTX) toxicity in mice using continuous infusions. Uitendaal MP; Schornagel JH; Leyva A; Pinedo HM Adv Exp Med Biol; 1984; 165 Pt B():401-5. PubMed ID: 6720437 [No Abstract] [Full Text] [Related]
6. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388. Góra-Tybor J; Robak T Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the 3'-chloroethylnitrosourea analog of thymidine and the prevention by co-administered thymidine of lethality but not of anticancer activity. Lin TS; Fischer PH; Marsh JC; Prusoff WH Cancer Res; 1982 May; 42(5):1624-9. PubMed ID: 7066884 [TBL] [Abstract][Full Text] [Related]
8. Effect of thymidine on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II). Grossie VB; Valdivieso M; Drewinko B; Loo TL Cancer Chemother Pharmacol; 1984; 13(1):27-30. PubMed ID: 6539657 [TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity of the bitter melon (Momordica charantia). Jilka C; Strifler B; Fortner GW; Hays EF; Takemoto DJ Cancer Res; 1983 Nov; 43(11):5151-5. PubMed ID: 6616452 [TBL] [Abstract][Full Text] [Related]
10. Effect of 3'-amino-3'-deoxythymidine on L1210 and P388 leukemias in mice. Lin TS; Fischer PH; Prusoff WH Biochem Pharmacol; 1982 Jan; 31(1):125-8. PubMed ID: 7059345 [No Abstract] [Full Text] [Related]
11. Effects of allopurinol on the therapeutic efficacy of methotrexate. Grindey GB; Moran RG Cancer Res; 1975 Jul; 35(7):1702-5. PubMed ID: 1131828 [TBL] [Abstract][Full Text] [Related]
12. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice. Warzocha K; Robak T Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753 [TBL] [Abstract][Full Text] [Related]
13. Enhancement of the therapeutic effectiveness of methotrexate and protection of normal proliferating tissues with purines and pyrimidines. Harrap KR; Taylor GA; Browman GP Chem Biol Interact; 1977 Jul; 18(1):119-28. PubMed ID: 302148 [TBL] [Abstract][Full Text] [Related]
14. [Effects of combination chemotherapy of MCNU with various anti-cancer agents]. Machida S; Ito Y; Hoshino A Gan To Kagaku Ryoho; 1985 Feb; 12(2):298-302. PubMed ID: 3918506 [TBL] [Abstract][Full Text] [Related]
15. [Antitumor effect of methylene blue in vivo]. Lai BT Zhonghua Zhong Liu Za Zhi; 1989 Mar; 11(2):98-100. PubMed ID: 2806052 [TBL] [Abstract][Full Text] [Related]
16. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice. Samuels LL; Straw JA Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764 [TBL] [Abstract][Full Text] [Related]
17. Combination of 5-fluorouracil and cyclophosphamide in L1210 and P388 leukemias with changes in optimum treatments as a function of the age of the L1210 tumor at first treatment. Wampler GL; Carter WH; Campbell ED Cancer Invest; 1987; 5(6):523-33. PubMed ID: 3442730 [TBL] [Abstract][Full Text] [Related]
18. Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388. Marañda E; Szmigielska A; Robak T Cancer Invest; 1999; 17(2):95-101. PubMed ID: 10071592 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Elliott WL; Roberts BJ; Howard CT; Leopold WR Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790 [TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta. Borden EC; Sidky YA; Hatcher JF; Bryan GT Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]